Jay Patel, MD
Ophthalmology · Pasadena, CANPI 1194958959
Payments from drug & device makers
Across 365 payments — averaging $523.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$122K
- Ocular Therapeutix, Inc.$44K
- Johnson & Johnson Surgical Vision, Inc.$7K
- Oyster Point Pharma, Inc.$5K
- Glaukos Corporation$3K
- Alcon$3K
- plus $7K from 24 others
Across 1 payment — averaging $3050.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$3K
What the payments were for
- Food & beverage$14,377100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 86 | $122,256 |
| Ocular Therapeutix, Inc. | 6 | $43,554 |
| Johnson & Johnson Surgical Vision, Inc. | 22 | $7,369 |
| Oyster Point Pharma, Inc. | 5 | $4,673 |
| Glaukos Corporation | 18 | $3,370 |
| Alcon | 59 | $2,586 |
| Sun Pharmaceutical Industries Inc. | 26 | $1,149 |
| Sight Sciences, Inc. | 21 | $874 |
| Novartis | 21 | $666 |
| Ivantis, Inc | 14 | $598 |
| Bausch & Lomb Americas Inc. | 12 | $585 |
| Dompe US, Inc. | 14 | $532 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $520 |
| Amgen(2 entities) | 10 | $401 |
| Eyevance Pharmaceuticals LLC | 8 | $353 |
| Eyepoint US, Inc. | 4 | $283 |
| Tarsus Pharmaceuticals, Inc. | 6 | $230 |
| Aerie Pharmaceuticals, Inc. | 6 | $209 |
| Thea Pharma Inc. | 3 | $159 |
| Nevro Corp. | 2 | $155 |
| Samsara Vision | 4 | $144 |
| Rxsight Inc | 1 | $136 |
| Shire North American Group Inc | 2 | $132 |
| Carl Zeiss Meditec, Inc. | 1 | $125 |
| Astellas Pharma US Inc | 1 | $34 |
| Harrow Eye, LLC | 1 | $29 |
| TEI Biosciences Inc | 1 | $28 |
| Omeros Corporation | 1 | $20 |
| Biotissue Holdings Inc. | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$1,014
- Hydrus Microstent$662
- OMNI(R) SURGICAL SYSTEM (US)$535
- iStent inject Trabecular Micro-Bypass Stent System$476
- iStent infinite Trabecular Micro-Bypass System Model iS3$409
- CEQUA$372
- XIIDRA$343
- STELLARIS$262
- TEPEZZA$250
- VYZULTA$243
- Rocklatan$242
- Rhopressa$242
- CATALYS SYSTEM$231
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$205
- Flarex$201
- VUITY$150
- ILUMYA$150
- Oxervate$136
- RXSIGHT CONTACT LENS$136
- RXSIGHT INJECTOR CARTRIDGE$136
How this compares
$191,203 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 147 | $130,957 |
| XiidraLifitegrast | 71 | $71,473 |
| Prednisolone Acetate | 1,830 | $59,745 |
| Cyclosporine | 137 | $57,089 |
| LumiganBimatoprost | 57 | $27,098 |
| CequaCyclosporine | 20 | $17,954 |
| Ofloxacin | 1,459 | $16,395 |
| MieboPerfluorohexyloctane/Pf | 13 | $9,797 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $8,690 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $7,965 |
| Latanoprost | 696 | $7,455 |
| TyrvayaVarenicline Tartrate | 11 | $6,943 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $6,771 |
| Fluorometholone | 82 | $6,072 |
| Alphagan PBrimonidine Tartrate | 25 | $5,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $122,256 | $172,382252 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $585 | $84,96395 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,149 | $17,95420 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $209 | $12,14331 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $4,673 | $6,94311 claims |
| AlconSimbrinza | $2,586 | $6,77126 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $520 | $1,67111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Pasadena
- Michael IpPasadena$10.2M
- Srinivas SaddaPasadena$1.3M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.